UnitedHealth Group Shares Down 1% - Should You Sell?

Analysts weigh in on the healthcare company's stock performance.

Mar. 10, 2026 at 9:36pm

Got story updates? Submit your updates here. ›

UnitedHealth Group (NYSE:UNH) shares traded down 1% during mid-day trading on Tuesday, with the stock hitting a low of $278.90 and closing at $282.23. Trading volume declined 39% from the average session. Analysts have issued mixed ratings on the stock, with some maintaining a 'Buy' recommendation and others downgrading it to 'Sell'.

Why it matters

UnitedHealth Group is a major player in the healthcare industry, providing insurance and other services. Its stock performance is closely watched as an indicator of the broader sector. The stock's recent decline raises questions about whether investors should consider selling their shares.

The details

Several research analysts have adjusted their price targets for UnitedHealth Group. Morgan Stanley dropped its price objective from $411 to $409, while Jefferies Financial Group reduced its target from $418 to $340. The stock currently has an average rating of 'Moderate Buy' and a consensus target price of $372.13.

  • UnitedHealth Group shares traded down 1% during mid-day trading on Tuesday, March 10, 2026.

The players

UnitedHealth Group

A diversified healthcare company that operates two primary business platforms: UnitedHealthcare and Optum.

Morgan Stanley

A financial services firm that has issued a research report on UnitedHealth Group.

Jefferies Financial Group

A financial services firm that has issued a research report on UnitedHealth Group.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The mixed analyst sentiment and stock price decline for UnitedHealth Group raise questions about the company's near-term outlook and whether investors should consider selling their shares. However, the healthcare sector remains a closely watched industry, and UnitedHealth Group's long-term performance will likely depend on broader industry trends and the company's ability to navigate a changing regulatory environment.